Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

- Iland, Harry J., Collins, Marnie, Hugman, Amanda, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bradstock, Ken, Bashford, John, Seymour, John F., Supple, Shane G., Catalano, Alberto, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Campbell, Lynda J.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

- Iland, Harry J., Bradstock, Ken, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bashford, John, Supple, Shane G., Seymour, John F., Catalano, Alberto, Collins, Marnie, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Hugman, Amanda

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

- Hughes, Timothy P., Branford, Susan, Cooney, Julian, Leahy, Michael F., Rowlings, Philip, Catalano, John, Hertzberg, Mark, Filshie, Robin, Mills, Anthony K., Fay, Keith, Durrant, Simon, Januszewicz, Henry, White, Deborah L., Joske, David, Underhill, Craig, Dunkley, Scott, Lynch, Kevin, Grigg, Andrew, Reynolds, John, Koelmeyer, Rachel, Seymour, John F., Taylor, Kerry, Arthur, Chris, Schwarer, Anthony K., Morton, James